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Original Article
Does choice of therapy save costs and improve outcomes in hyperthyroid patients?
Lubna M. Zuberi, Safia Awan, Najmul Islam, Jaweed Akhter, Abdul Jabbar
Department of Medicine, Aga Khan University, Karachi.

Abstract
Objective: To compare cost of treating hyperthyroidism with antithyroid medications (ATD) versus radioactive
iodine (RAI). As secondary outcome we also analyzed data in terms of remission rates.
Methods: This was a retrospective comparative analysis of hyperthyroid patients treated with ATD or RAI from
January 2000 to December 2005. Cost of ATD, TSH. FT4, doctors visits; thyroid technetium scan and RAI
treatment were calculated for the duration of treatment and for one year of follow-up after remission.
Results: A total of 143 patients were included, with an average duration of follow-up of 32 months. Mean age
was 41 ± 15.5 years and M: F' ratio was 1: 2. More expenses were incurred in treating patients with ATD (Rs.
28,900 ± 15 400 or US$ 481.67 ± 256.67) than with RAI (Rs.l8.800± 15800 or US$313.33± 263.33). The former
cost Rs.l0,100 (US$ 168.33) more, (p< 0.001; 95%). Remission rate in the RAI group were significantly higher
than the ATD group (81.3% vs 49.5%, p=0.006).
Conclusion: Treatment of hyperthyroid patients with RAI is not only better in terms of remission of disease, but
it is also a more cost effective modality, and should be considered as first line of treatment (JPMA 58:309;2008).

Introduction
Hyperthyroidism was clinically recorded as a
disease entity nearly two centuries ago, and means of
medical treatment discovered nearly 70 years back.
Currently there are two modes of medical therapy available;
antithyroid medications and radioactive iodine. Debate
rages over which treatment is better in terms of producing
long term remission and causing fewer side effects (short
and long term). For a developing country like Pakistan, an
important aspect of treating any medical condition also
includes the cost, not only of treatment, but also of
diagnostic testing. Literature is scant about the "cost
effectiveness" of various treatment modalities. Models

exist, which extrapolate costs and feasibility from
hypothetical cases, but for physicians sitting in their clinics
, and patients who pay out of pocket for their treatment, a
realistic approach which considers the "actual" rather than
the "hypothetical extrapolation" of cost needs objective
evaluation.
The purpose of this study was to analyse the cost
incurred in the medical treatment of patients with
hyperthyroidism to see if one treatment is superior to the
other. As secondary outcome we also analyzed data in terms
of remission rates.

Methods
This was a retrospective analysis of patient's records
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from Jan 2000 to December 2005. All patients with
diagnosed hyperthyroidism seen at the endocrine clinic at
Aga Khan University Hospital, were recruited for
consideration into this study. Those considered for the
analysis, had to have a minimum follow-up of at least one
year after their diagnosis and treatment. We excluded
children (below 16 years of age), patients with post partum
thyroiditis, sub acute thyroiditis, iatrogenic hyperthyroidism
and those who had surgical treatment of hyperthyroidism. In
addition to demographic variables we recoded the number
and frequency of thyroid function test that they had;
Thyroid Stimulating Hormone (TSH), Total or free T4
(FT4) and total or free T3. We also made note of the number
of total doctors visits and average number of doctors visits.
If they had had a thyroid technetium scan or treatment with
radioactive iodine, this was recorded separately. We
determined an arbitrary cost for the tests and doctors visits
(as this may change from institution to institution and also
might be revised from year to year). The cost of checking
serum TSH, FT4 and T3 was considered at Rs 500 each.
One doctor's visit was Rs. 650. Cost of thyroid technetium
scan was Rs. 4000/- and that for I131 treatment also at PKR
4000 (US$ 66.67).
A descriptive analysis was done for demographic
and clinical features and results are presented as mean ±
standard deviation for quantitative variables and number
(percentage) for qualitative variables. In univariate
analyses, differences in proportions for types of treatment
were assessed by using the Chi-square test or Fisher exact
test where appropriate. For contrasts of continuous
variables, independent sample t-test was used to assess the
difference of means.
All analyses were conducted by using the
Statistical package for social science SPSS (Release I
1.5.0. standard version, copyright © SPSS: 1989-02). All
p-values were two sided and considered as statistically
significant if < 0.05.

Results
A total of 143 cases were included in the study.
Majority of the cases were reported to have Graves disease
(42%), with 19% diagnosed with toxic nodule or toxic
multinodular goiter. The remainder did not have the cause
of their hyperthyroidism listed in their records, nor had a
thyroid technetium scan or thyroid microsomal antibodies
(also known as thyroid peroxide antibodies) checked to
allow the researchers to assign the subject with a diagnosis.
Average duration of follow up was 32 months. Mean age of
the group was 40.97 + 15.51 years. Two thirds of the
patients were women and a third were males, and 18% were
single. Nearly all the patients were treated with antithyroid
medications as initial choice, with 92% receiving either
310

Table. Demographic and outcomes data in hyperthyroid patients.
Aiitithyroid
medications

Radioactive
iodine

(N = 111)

(N -32)

Mean Age (years)

40.53 ± 15.6

42.50 ± 15.3

0.52

Male: female ratio

2.9 : 7.1

5.3 : 4.7

0.01

Mean duration of
follow up (months)

3 1 .34

34.77

0.45

Remission rates (%)
[Number in
remission/number
treated]

49.5%
[55/111]

81.3%
[26/32]

0.006

Average cost of
28,900 ± 15,400 18,800 ± 13,400
treatment (per patient),
in rupees

P value

0.001

p < 0.05 considered significant.

neomercazole or propylthiouracil as the initial treatment.
Only twelve patients (8%) were treated with I131 initially.
An additional twenty two (15%) were given treatment with
I131, once they did not go into remission with anti thyroid
medications.
Table shows the demographic and outcomes data.
There was a significantly higher remission rate in those
treated with I131 when compared to the group receiving ATD
(81.3% vs 49.5%, p=0.006). Post ablative hypothyroidism
was seen in 68.8% of those treated with radioactive iodine.
Males were more likely to be offered treatment with
radioactive iodine and received the same, as compared to
female patients. There were 53.1% males and 28.8%
females who received I131 as opposed to 46.9% males and
71.2% females treated with antithyroid medications
(p=0.01). There was no relationship of age with the
preferred treatment.
Mean cost of treating patients with hyperthyroidism
was PKR 21,070 ± 1422 (US$ 351 ± 23.7%). The major
expense to the cost was from diagnostic lab testing, with
cost of thyroid function testing contributing to 48.8% of the
total, followed by doctors fee from clinic visits (36.36%).
Antithyroid medications contributed the least amount to the
cost (about 8.13%). Radiologic investigation were
requested in only 38 patients and contributed to another
6.71% of overall expenses.
There was a significant difference in the expense
incurred between two modalities of treatment. Treatment
with antithyroid medications was more expensive by PKR
10,100 (US$ 168.33), as the average cost of this treatment
modality was PKR 28,900 ± 15,400 (US$ 481.67 ± 256.67),
as opposed to I131 which cost the patient PKR 18,800 ±
15,800 (US$ 313.33 ± 263.33), p< 0.001; 95% CI. The

J Pak Med Assoc

underlying cause of hyperthyroidism, age or sex of the
patient, their marital status did not influence the choice of
treatment.

Discussion
Thyrotoxicosis exists in 2% of women and 0.2% of
men.1 Graves disease is seen most commonly between the
second and the fourth decades of life and toxic multinodular
goiter (toxic MNG)and toxic adenoma are seen with
increasing age. Literature from Europe and North America
places Graves as the most common cause of
hyperthyroidism, responsible for 85% of all hyperthyroid
patients.2 The prevalence of toxic adenoma and TMN goiter
depends on the degree of iodine sufficiency of a region and
accounts for 7 -11% of all hyperthyroid patients.3 Regional
data regarding the etiology of hyperthyroidism is scant and
derived from select patient populations (i.e. patients
referred for surgery, or pediatric patients). Nonetheless this
shows that prevalence of toxic MNG is much higher.4 Even
though Graves disease as a cause of hyperthyroidism was
the most frequent, prevalence of multinodular goiter is
higher than that reported from the west; 19% as opposed to
7 - 11%.
Diagnostic lab testing was responsible for nearly
half of the incurred costs, followed by doctors visits. So
even though thionamides are affordable and accessible
treatment modality and preferred by many as first line in the
South Asian region, yet in the long term prove to be cost
ineffective, as most of those on anti thyroid medications
require longer follow-up and on going medical care. A
difference of PKR 10,000 (US$ 167.67) is significant for
most individuals in a region where per capita income is US$
847.5 This coupled with the higher remission rates in those
treated with radioactive iodine as opposed to those treated
with anti thyroid medications, argues for the use of I131
more frequently.
Qari et al have observed a significant cost benefit of
treating patients with radioactive iodine, showing this
modality to be the most cost effective at 1700 Saudi Riyals.
Cost of medical treatment was eight times as expensive.6
Clearly its use needs to be targeted to the right patient, and
should take into account not only chances of remission ,
based on goiter size, underlying pathology, age and
autoimunity, but also the cost of long term follow-up. A
group from Germany, using costing models that included
follow up care for 30 years, showed radioiodine to be a cost
effective first line therapy in patients with a special risk of
relapse after primary conservative therapy ( large goiter,
younger age, persistently elevated TSH receptor antibodies
or high technetium uptake).7 In their study anti thyroid
drugs were considered cost effective only if they achieved a
relapse rate of less than 50%, a cut in number of tests
Vol. 58, No. 6, June 2008

needed and reduced number of hours absent from work . A
cost utility analysis of 1000 hypothetical patients diagnosed
with Graves disease at the age of 30 years, and then
followed up as a cohort for 40 years quantitatively
demonstrated that I 131 therapy was superior to ATD in both
costs and utility.8 Analytic models examining the cost
effectiveness of different therapeutic strategies in patients
with toxic adenoma found surgery to be most effective and
the least costly strategy for younger patients, while
radioiodine the less costly for elderly.9 This model took into
consideration the cost of co morbidities and expected
mortality risk from surgical intervention.
The debate about which therapy has better outcome
continues, and geographical differences exist based partially
on epidemiological differences, patients age and
preferences, local traditions and glandular size. Sixty-nine
percent of thyroidologists in USA prefer I131 for treating a
40 year old woman with Graves10 while seventy-seven
percent of their European colleagues prefer antithyroid
medications11, as do the majority in Japan (eighty-eight
percent).12 A prospective, randomized study to objectively
examine the benefits and risks of different treatment
modality, conducted by Torring et al and the Thyroid Study
group.13 showed that the risk of relapse was highest in the
medically treated young and old adults. Patient satisfaction
was 90% and did not differ with respect to the treatment
modality chosen.
A few limitations are inherent in this study based on
its retrospective nature. In addition patients were not
grouped according to disease etiology and analysed based
on their cause of hyperthyroidism. The incidence of post
ablative hyperthyroidism remains high in those treated with
radioactive iodine, and this will need to be borne in mind.

Conclusion
Sufficient data exists to show better remission rates
of hyperthyroid patients with radioactive iodine. The
additional advantage of cost savings in the long term is also
an important consideration. This study has shown a
significant cost benefit of radioactive iodine over anti
thyroid medication. The choice of therapy should not only
be guided by underlying pathology, patients age, goiter size,
severity of hyperthyroidism and level of thyroid antibodies
(specifically TSH receptor antibodies), but also the long
term costs in economically disadvantaged regions of the
world.
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Original Article
Knowledge, attitude and perception of water pipe smoking (Shisha) among
adolescents aged 14-19 years
Qudsia Anjum1, Farah Ahmed2, Tabinda Ashfaq3
Department of Community Health Sciences1,2, Department of Family Medicine3, Ziauddin University, Karachi.

Abstract
Objective: To study the impact of educational intervention on knowledge, attitude and practices with regard to
water pipe smoking among adolescents (14-19 years old) in Karachi.
Methods: A cross-sectional survey of adolescents aged 14-19 years studying at different educational institutions
of Karachi, Pakistan was conducted through multistage sampling on a pre-tested self-administered
questionnaire. They were divided into high, middle and lower socioeconomic strata on the basis of monthly fee
structure. The impact of health messages was assessed two months after education sessions through post-test
of only high and middle socioeconomic strata.
Results: A total of 646 students were surveyed for the pre test and 250 students for the post test. A significant
association was found for water pipe smoking among the socioeconomic class (p<0.001). Water pipe is more
addictive as compared to cigarettes was marked by more students after the sessions (54% vs 68%; p<0.001). A
significant difference was seen for water pipe being more socially acceptable (58% vs 80%; p<0.001), it is part
of our cultural heritage (29% vs 58%; p<0.001).
Conclusion: Shisha smoking was more prevalent among the high socio economic group, which might be
because of the cost, accessibility and availability. The knowledge of the students regarding water pipe smoking
improved after the health awareness sessions (JPMA 58:312;2008).

Introduction

Peninsula, Turkey, India, Pakistan, Bangladesh and China.1

Water pipe smoking known by a variety of names
like Shisha, Narghile, Ghoza, Hubble bubble and Hookah is
in vogue for the last many centuries. Its origin from one
historical account suggested that it was invented in India by
a physician Hakim Abul Fath during the reign of Emperor
Akbar as a less harmful method of tobacco use.1 But some
suggested that it was first used in South Africa, Persia,
Ethiopia and other countries.2 It has been claimed that
greater than 100 million people worldwide smoke water
pipe.2 It has been a common practice in the Arabian

In the subcontinent, water pipe traditionally known
as Hookah has been part of culture in most rural areas. It is
gaining popularity among the youth very recently especially
in urban cities. Commonly known as shisha, this trend has
started with mushrooming Arabian shisha cafes opening in
posh localities. The target was the young generation but
unfortunately adolescents and children have also been
indulging in shisha smoking. Its acceptance socially might
be because it is part of our cultural heritage. Other factors
for its popularity include easy availability, attractive designs
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